Bioventus Inc. (NYSE:BVS) Shares Sold by Cubist Systematic Strategies LLC

Cubist Systematic Strategies LLC trimmed its holdings in Bioventus Inc. (NYSE:BVS) by 19.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 40,163 shares of the company’s stock after selling 9,659 shares during the quarter. Cubist Systematic Strategies LLC owned approximately 0.05% of Bioventus worth $231,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of BVS. Mackenzie Financial Corp purchased a new position in Bioventus in the 2nd quarter valued at $77,000. The Manufacturers Life Insurance Company purchased a new position in Bioventus in the 2nd quarter valued at $87,000. Squarepoint Ops LLC grew its position in Bioventus by 13.8% in the 2nd quarter. Squarepoint Ops LLC now owns 26,171 shares of the company’s stock valued at $150,000 after buying an additional 3,170 shares during the last quarter. Marshall Wace LLP grew its position in Bioventus by 38.2% in the 2nd quarter. Marshall Wace LLP now owns 332,291 shares of the company’s stock valued at $1,911,000 after buying an additional 91,843 shares during the last quarter. Finally, Bank of Montreal Can purchased a new position in Bioventus in the 2nd quarter valued at $774,000. 62.94% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Bioventus news, Director John A. Bartholdson acquired 80,000 shares of the firm’s stock in a transaction that occurred on Friday, August 16th. The shares were acquired at an average cost of $8.55 per share, for a total transaction of $684,000.00. Following the transaction, the director now directly owns 6,913,857 shares of the company’s stock, valued at approximately $59,113,477.35. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other Bioventus news, Director John A. Bartholdson acquired 25,500 shares of the firm’s stock in a transaction that occurred on Monday, August 19th. The shares were acquired at an average cost of $8.55 per share, for a total transaction of $218,025.00. Following the transaction, the director now directly owns 6,939,357 shares of the company’s stock, valued at approximately $59,331,502.35. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director John A. Bartholdson acquired 80,000 shares of the firm’s stock in a transaction that occurred on Friday, August 16th. The stock was acquired at an average price of $8.55 per share, for a total transaction of $684,000.00. Following the completion of the transaction, the director now directly owns 6,913,857 shares in the company, valued at approximately $59,113,477.35. This represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 32.90% of the company’s stock.

Analyst Ratings Changes

BVS has been the topic of a number of analyst reports. Craig Hallum lifted their price objective on shares of Bioventus from $12.00 to $17.00 and gave the company a “buy” rating in a research report on Friday, September 27th. Canaccord Genuity Group lifted their price objective on shares of Bioventus from $8.00 to $12.00 and gave the company a “buy” rating in a research report on Tuesday, August 13th.

Bioventus Price Performance

Shares of NYSE BVS opened at $12.57 on Tuesday. The firm has a market capitalization of $995.12 million, a P/E ratio of -35.91 and a beta of 0.90. Bioventus Inc. has a one year low of $2.88 and a one year high of $12.68. The company’s fifty day moving average is $10.23 and its two-hundred day moving average is $7.39. The company has a debt-to-equity ratio of 1.82, a quick ratio of 0.96 and a current ratio of 1.33.

Bioventus (NYSE:BVS) last issued its earnings results on Tuesday, August 6th. The company reported $0.19 EPS for the quarter, topping the consensus estimate of $0.07 by $0.12. The company had revenue of $151.22 million for the quarter, compared to analyst estimates of $137.70 million. Bioventus had a negative net margin of 7.82% and a positive return on equity of 14.39%. During the same period in the previous year, the firm earned $0.14 EPS. Analysts forecast that Bioventus Inc. will post 0.4 EPS for the current fiscal year.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.